case_images: PMC10601772_01
case_images: An overview of the primary lesion in the upper lobe of the right lung at different time points before and after SARS-CoV-2 vaccination (vaccine BNT162b2). a Computed tomography (CT) images prior to the initiation of pembrolizumab treatment showing a 7.7-cm large mass with chest wall infiltration in the upper lobe of the right lung. b CT images after 59 courses of pembrolizumab treatment showing, that the primary lesion is approximately 3 cm long with calcification. c CT images weeks after vaccination showing no significant changes in the primary lesion, whereas fluid retention and consolidation can be seen adjacent to it. d CT images 3 months after vaccination, showing that the fluid retention and consolidation seen in c have improved, and the primary lesion is smaller than before vaccination. e CT images at the time of course 70 showing further reduction of the primary lesion.
case_images: cro-2023-0016-0001-533705_F01.jpg
case_images: PMC10601772_01_cro-2023-0016-0001-533705_F01.jpg
case_images: F1
case_images: T3N0M1c (metastases in the mesenteric lymph nodes and small intestine) stage 4B right upper lobe lung adenocarcinoma and a PD-L1 tumor proportion score of 100% (Fig. 1a). CT showed that the tumor maintained a partial response between courses 8 and 59 (Fig. 1b). On routine follow-up CT performed several weeks after the second dose, no significant changes in the primary lesion were seen, but adjacent fluid retention and consolidation were observed (Fig. 1c). The primary lesion size (Fig. 1d), continued to decrease up to course 65 and then stabilized again.